| Literature DB >> 35904700 |
Amaya Jimeno-Almazán1,2, Alejandro Martínez-Cava1, Ángel Buendía-Romero1, Francisco Franco-López1, José Antonio Sánchez-Agar1,3, Bernardino Javier Sánchez-Alcaraz1, James J Tufano4, Jesús G Pallarés1, Javier Courel-Ibáñez5.
Abstract
The aim of this study was to determine the relationship between physical fitness, cardiopulmonary function and patient-reported severity of symptoms in people with post-COVID-19 condition. We examined ambulatory patients (n = 72) with post-COVID-19 condition who had a chronic symptomatic phase lasting > 12 weeks from the onset of symptoms, but had not been hospitalized for acute COVID-19. A comprehensive medical screening was conducted, including clinical history, symptomatology, comorbidities, body composition and physical activity levels. We then identified the relationship between physical fitness (cardiorespiratory fitness and muscular strength), cardiopulmonary function (echocardiographic and spirometry parameters) and patient-reported severity of symptoms (fatigue, dyspnea, health-related quality of life, anxiety, and depression). Age, body mass index, sex, number of comorbidities and duration of symptoms were included as potential confounders. Results showed that greater physical fitness and cardiopulmonary function were associated with lower severity of symptoms in people with post-COVID-19 condition. Cardiorespiratory fitness, lower-limb muscle strength, maximal voluntary ventilation and left ventricular ejection fraction account for reducing fatigue and dyspnea. Greater physical activity levels were associated with fewer symptoms and less-severe fatigue and dyspnea. In conclusion, preserving better cardiopulmonary health and physical condition during the course of the disease-even in mild cases-was related to a lower intensity of symptoms in non-hospitalized people with post-COVID-19 condition. It is probable that exercise and physical conditioning are valuable pre- and post-COVID-19 countermeasures that could help decrease the severity, not only of acute infection, but of post-COVID-19 persistent symptoms and prognosis.Entities:
Keywords: Breathlessness; Fatigue; Long COVID-19; Post-COVID-19 syndrome; Post-exercise malaise; Rehabilitation
Year: 2022 PMID: 35904700 PMCID: PMC9335466 DOI: 10.1007/s11739-022-03039-0
Source DB: PubMed Journal: Intern Emerg Med ISSN: 1828-0447 Impact factor: 5.472
Characteristics, medical screening, clinical history and symptomatology of people with post-COVID-19 condition (n = 72)
| Characteristics | Value | Characteristics | Value |
|---|---|---|---|
| Age (years) | 45.5 ± 9.0 | Symptom’s length (weeks) | 36.3 ± 21.1 |
| Sex | Number of symptoms ( | 7.7 ± 3.4 a,b | |
| Men | 25 (34.7) | Symptoms ( | |
| Women | 47 (65.3) | Fatigue | 60 (83.3) |
| Occupational status ( | Dyspnea | 49 (68.0) | |
| Employed | 38 (52.8) | Memory problems or confusion | 44 (61.1) |
| Sick leave | 25 (34.7) | Insomnia or sleep disturbances | 42 (58.3) |
| Unemployed | 9 (12.5) | Lack of concentration | 41 (56.9) |
| Body composition | Brain fog | 40 (55.5) | |
| Body mass (kg) | 74.7 ± 14.3 | Myalgia | 40 (55.5)c |
| Height (cm) | 166.4 ± 9.0 | Low mood | 38 (52.7)d |
| BMI (kg·m−2) | 26.9 ± 4.8 | Headache | 34 (47.2) |
| Fat mass (%) | 31.7 ± 8.2 | Anxiety | 31 (43.0)d |
| Lean body mass (kg) | 49.8 ± 10.5 | Loss of smell/taste | 25 (34.7) a |
| Toxic Habits ( | Hair loss | 21 (29.1) a | |
| Alcohol | 8 (11.1) | Dizziness | 19 (26.3) |
| Drink units (SDU) | 3.75 (1.9) | Chest pain | 19 (26.3) a |
| Active smoker | 4 (8.0) | Palpitations | 17 (23.6) |
| Former smoker | 22 (30.5) | Abdominal pain | 12 (16.6) |
| Comorbidity ( | Diarrhea | 11 (15.2) | |
| Any comorbidity | 42 (58.3) | Loss of appetite | 11 (15.2) |
| Psychiatric conditions | 28 (38.8) | Low grade fever | 10 (13.8) |
| Asthma | 11 (15.2) | Weight loss | 10 (13.8) |
| Hypertension | 6 (8.3) | Cough | 10 (13.8) a |
| Structural heart disease | 4 (5.5) | Nausea and/or vomiting | 3 (4.1) |
| Diabetes | 3 (4.1) | Evolution ( | |
| COPD | 2 (2.7) | Fluctuating course | 36 (50.0) |
| Medication ( | Progressive improvement | 53 (73.6) | |
| Taking medication | 49 (69.0) | Vaccination | 40 (56.6) |
| Antidepressants | 21 (29.1) | Reinfection | 7 (9.7) |
| Benzodiazepines | 21 (29.1) | Physical activity (min·wk-1) | |
| Bronchodilators | 15 (20.8) | Moderate | 268 ± 343 |
| Thorax X-ray at diagnosis ( | 52 (72.2) | Vigorous | 83 ± 213 |
| Pneumonia ( | 6 (8.3) | Meet OMS recommendations | 42 (58.3) |
| Sedentary (hours) | 6.5 ± 3.6 |
aSignificant sex differences (p < 0.05)
bSignificant association with physical activity levels (p < 0.05)
cSignificant association with vaccination (p < 0.05)
dSignificant association with previous psychiatric conditions (p < 0.05). Data are means and standard deviation (M ± SD) or frequencies and percentages (n (%))
BMI Body mass index, SDU (Standard Drink Unit) Spanish standard unit is equivalent to 10 g of alcohol, COPD Chronic Obstructive Pulmonary Disease
Physical fitness, cardiopulmonary function and severity of symptoms in people with post-COVID-19 condition (n = 72)
| Physical fitness | Value | Cardiopulmonary function | Value | Severity of symptoms | Value |
|---|---|---|---|---|---|
| Initial work rate (W) | 73.4 ± 23.7 | FVC (L) | 3.7 ± 0.9 | CFQ-11 | 8.0 ± 3.0 |
| Higher work rate (W) | 98.6 ± 25.9 | % FVC | 95.8 ± 14 | FSS | 5.3 ± 1.4 |
| Initial RPE | 12.5 ± 2.0 | FEV-1 (L) | 3.1 ± 0.8 | DSQ-14 | 55.3 ± 18.4 |
| Initial HR (b·m−1) | 121.3 ± 13.9 | % FEV-1 | 104.8 ± 17.1 | PCFS | 2.4 ± 0.9 |
| Final HR (b·m−1) | 143.6 ± 16.0 | FEV/FVC | 84.5 ± 7.2 | mMRC | 1.4 ± 0.9 |
| Final RPE | 15.1 ± 1.5 | FEV 25–75% (L·s−1) | 3.7 ± 1.2 | SF-12 PCS | 35.9 ± 11.1 |
| VO2max (ml·kg·min−1) | 35.8 ± 10.4 | MVV (L) | 102.2 ± 38.4 | SF-12 MCS | 41.8 ± 12.0 |
| Sit-to-stand (s) | 7.6 ± 2.8 | % MVV | 87.2 ± 23.1 | PHQ-9 | 12.1 ± 5.6 |
| Handgrip (kg) | 32.8 ± 10.1 | LVEF (%) | 61.6 ± 5.1 | GAD-7 | 9.4 ± 5.2 |
| BP-50% 1RM (kg) | 17.3 ± 9.3 | RV-TAPSE (mm) | 24.0 ± 3.1 | ||
| HSQ-50% 1RM (kg) | 17.8 ± 14.2 | LVEDV (cm−3m−2) | 48.4 ± 10.1 | ||
| Leg extension (N) | 416.9 ± 148.9 | E/A (cms−1) | 1.3 ± 0.5 |
Data are means and standard deviation (M ± SD) or frequencies and percentages (n (%))
HR Heart rate. VO2max: Maximum oxygen uptake estimated by sex-specific equations [34]. HG Handgrip, BP Bench Press, HSQ Half Squat, FVC Forced ventilatory capacity, FEV Forced expiratory volume, MVV Maximum voluntary ventilation, LVEF Left Ventricular Ejection Fraction, RV-TAPSE Right ventricular- Tricuspid Annular Plane Systolic Excursion, LVEDV Left Ventricular End Diastolic Volume, E/A ratio early diastolic velocity (E), late diastolic velocity (A), CFQ-11 Chalder Fatigue Scale, FSS Fatigue Severity Scale, DSQ-14 The DePaul Symptom Questionnaire, PCFS Post-COVID-19 Functional Status scale, mMRC Modified Medical Research Council dyspnea scale, PCS Physical health component score, MCS Mental health component score, PHQ Patient Health Questionnaire, GAD Generalized Anxiety Disorder scale
Fig. 1Heatmap shows the correlation between severity of symptoms, physical fitness, and cardiopulmonary function in people with post-COVID-19 condition (n = 72). Crossed (X) squares mean non-significant associations (p > 0.05)
Multiple linear regression examining the associations of symptoms severity with physical fitness, and cardiopulmonary function in people with post-COVID-19 condition (n = 72)
| Dyspnea | Fatigue | |||||||
|---|---|---|---|---|---|---|---|---|
| mMRC | CFQ-11 | FSS | DSQ-14 | |||||
| Physical fitness | ||||||||
| Higher Work rate (W) | − 0.04 | 0.869 | 0.07 | 0.770 | − 0.21 | 0.364 | − 0.17 | 0.377 |
| Final HR (b·m−1) | − 0.67 | 0.019* | − 0.11 | 0.700 | − 0.41 | 0.138 | − 0.34 | 0.151 |
| Final RPE (score) | − 0.24 | 0.211 | − 0.37 | 0.053 | − 0.21 | 0.240 | − 0.31 | 0.048* |
| VO2max (ml·kg·min−1) | − 1.12 | 0.027* | − 0.14 | 0.762 | − 0.36 | 0.445 | − 0.01 | 0.980 |
| Sit-to-stand (s) | 0.01 | 0.943 | 0.25 | 0.221 | − 0.08 | 0.674 | 0.21 | 0.202 |
| Handgrip (kg) | − 0.37 | 0.286 | 0.29 | 0.382 | − 0.32 | 0.338 | 0.14 | 0.616 |
| BP-50% 1RM (kg) | − 0.14 | 0.783 | − 0.72 | 0.150 | 0.22 | 0.648 | − 0.09 | 0.820 |
| HSQ-50% 1RM (kg) | − 0.18 | 0.578 | 0.39 | 0.220 | − 0.64 | 0.046* | − 0.14 | 0.587 |
| Leg extension (N) | − 0.05 | 0.847 | 0.08 | 0.749 | 0.37 | 0.118 | 0.24 | 0.237 |
| Adjusted | 0.28 | 0.30 | 0.33 | 0.51 | ||||
| Cardiopulmonary function | ||||||||
| FVC (L) | − 0.10 | 0.644 | − 0.57 | 0.021* | 0.30 | 0.133 | 0.22 | 0.260 |
| FEV-1 (L) | − 0.24 | 0.634 | − 0.47 | 0.376 | 0.44 | 0.345 | 0.40 | 0.373 |
| FEV/FVC | 0.04 | 0.768 | 0.16 | 0.278 | 0.21 | 0.112 | 0.06 | 0.620 |
| FEV 25–75% (L·s−1) | 0.31 | 0.112 | − 0.14 | 0.496 | 0.05 | 0.777 | − 0.06 | 0.710 |
| MVV (L) | − 0.57 | 0.013* | − 0.29 | 0.241 | − 0.76 | < 0.001* | − 0.46 | 0.024* |
| LVEF (%) | − 0.24 | 0.038* | − 0.01 | 0.986 | − 0.08 | 0.459 | − 0.21 | 0.049* |
| RV-TAPSE (mm) | − 0.05 | 0.717 | − 0.10 | 0.480 | 0.08 | 0.537 | 0.05 | 0.692 |
| LVEDV (cm−3·m−2) | 0.07 | 0.519 | 0.07 | 0.542 | − 0.01 | 0.945 | 0.15 | 0.125 |
| E/A (cm·s−1) | 0.16 | 0.294 | − 0.14 | 0.400 | − 0.19 | 0.184 | − 0.14 | 0.289 |
| Adjusted | 0.47 | 0.36 | 0.55 | 0.58 | ||||
β indicates standardized regression coefficients with significance levels of t. All the analyses were adjusted for age, body mass index, sex, number of comorbidities, and number of symptoms. All adjusted R2 values were significant; all P < 0.010
Variables excluded for collinearity (VIF > 10): Initial Work rate, Initial RPE, Initial HR, %FVC, FEV-1%, FEV-1, FEV/FVC, and %MVV
HR Heart rate, VO Maximum oxygen uptake estimated by sex-specific equations [34], HG Handgrip, BP Bench Press, HSQ Half Squat, FVC Forced ventilatory capacity, FEV Forced expiratory volume, MVV Maximum voluntary ventilation, LVEF Left Ventricular Ejection Fraction, RV-TAPSE Right ventricular-Tricuspid Annular Plane Systolic Excursion, LVEDV Left Ventricular End Diastolic Volume, E/A ratio early diastolic velocity (E), late diastolic velocity (A), CFQ-11 Chalder Fatigue Scale (bimodal), FSS Fatigue Severity Scale, DSQ-14 The DePaul Symptom Questionnaire (composite), mMRC Modified Medical Research Council) dyspnea scale